Literature DB >> 19074998

Unveiling a new essential cis element for the transactivation of the CYP3A4 gene by xenobiotics.

Takayoshi Toriyabe1, Kiyoshi Nagata, Tomonari Takada, Yusuke Aratsu, Tsutomu Matsubara, Kouichi Yoshinari, Yasushi Yamazoe.   

Abstract

Pregnane X receptor (PXR) has been shown to form a heterodimer with retinoid X receptor alpha (RXRalpha) and to bind to the distal nuclear receptor-binding element 1 and an everted repeat separated by six nucleotides in the proximal promoter of the CYP3A4 gene. In the present study, a new rifampicin-responsive region, located at -7.6 kilobases upstream from the transcription initiation site, has been identified using reporter assays in HepG2 cells. This region contains a cluster of possible nuclear receptor-binding half-sites, AG(G/T)TCA-like sequence. Of these putative half-sites, we focused six half-sites and termed them alpha-eta half-sites. Introduction of a mutation into either an alpha or beta half-site of CYP3A4 reporter genes almost completely diminished the rifampicin-induced transcription. In electrophoretic mobility shift assays, PXR/RXRalpha heterodimer bound to the direct repeat separated by four nucleotides (DR4) formed with alpha and beta half-sites. HepG2-based transactivation assays with the reporter gene constructs with or without mutations in the PXR binding element(s) demonstrated that this DR4 motif is essential for the transcriptional activation not only by rifampicin but also by various human PXR activators. In addition, reporter assays performed in human hepatocytes and mice with adenoviruses expressing luciferase derived from various CYP3A4 reporter genes and that expressing human PXR supported the results of experiments in HepG2 cells. These results suggest the obligatory role of the newly identified direct repeat separated by four nucleotides-type PXR binding element of the CYP3A4 gene for xenobiotic induction of CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074998     DOI: 10.1124/mol.108.050575

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes.

Authors:  Jian Yang; Xiaofei Luan; Haiyan Gui; Peng Yan; Dongfang Yang; Xiulong Song; Wei Liu; Gang Hu; Bingfang Yan
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Suppression of the pregnane X receptor during endoplasmic reticulum stress is achieved by down-regulating hepatocyte nuclear factor-4α and up-regulating liver-enriched inhibitory protein.

Authors:  Thaveechai Vachirayonsti; Karen W Ho; Dongfang Yang; Bingfang Yan
Journal:  Toxicol Sci       Date:  2015-01-22       Impact factor: 4.849

3.  Mechanisms of CYP3A Induction During Pregnancy: Studies in HepaRG Cells.

Authors:  Madhav Sachar; Edward J Kelly; Jashvant D Unadkat
Journal:  AAPS J       Date:  2019-03-27       Impact factor: 4.009

4.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

5.  Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis.

Authors:  Raj Vuppalanchi; Tiebing Liang; Chirayu Pankaj Goswami; Rohit Nalamasu; Lang Li; David Jones; Rongrong Wei; Wanqing Liu; Vishal Sarasani; Sarath Chandra Janga; Naga Chalasani
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

6.  Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor.

Authors:  Desirée Bartolini; Francesca De Franco; Pierangelo Torquato; Rita Marinelli; Bruno Cerra; Riccardo Ronchetti; Arne Schon; Francesca Fallarino; Antonella De Luca; Guido Bellezza; Ivana Ferri; Angelo Sidoni; William G Walton; Samuel J Pellock; Matthew R Redinbo; Sridhar Mani; Roberto Pellicciari; Antimo Gioiello; Francesco Galli
Journal:  J Med Chem       Date:  2020-03-20       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.